



Anti-MMAE monoclonal antibody, clone 3F3 (CABT-B8992)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Antigen Description	MMAE [BSA]
Target	Monomethyl auristatin E
Immunogen	MMAE [KLH]
Isotype	IgG1
Source/Host	Mouse
Species Reactivity	N/A
Clone	3F3
Affinity Constant	Kd > 2.76×10 ⁻⁹
Purification	Affinity Chromatography
Conjugate	Unconjugated
Applications	ELISA
Format	Liquid
Size	100 µl
Buffer	0.01M PBS
Preservative	None
Storage	4°C for 2 weeks, -80°C for 2 years.

BACKGROUND

Introduction Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody. It is a potent antimitotic drug derived from peptides occurring in marine shell-less mollusc *Dolabella auricularia* called dolastatins which show potent activity in preclinical studies, both in vitro and in vivo, against a range of lymphomas, leukemia and solid tumors. These drugs show potency of up to 200 times that of vinblastine, another antimitotic drug used for Hodgkin lymphoma as well as other types of cancer. MMAE is actually desmethyl-auristatin E; that is, the N-terminal amino group has only one methyl substituent instead of two as in auristatin E itself.

Keywords Monomethyl auristatin E
